RCMNY
CTMX icon

Rubric Capital Management (New York)’s CytomX Therapeutics CTMX Stock Holding History

Rubric Capital Management (New York)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,406,449
Closed -$3.85M – 76
2022
Q4 		$3.85M Hold
2,406,449
– – 0.17% 77
2022
Q3 		$3.49M Hold
2,406,449
– – 0.18% 72
2022
Q2 		$4.4M Hold
2,406,449
– – 0.23% 65
2022
Q1 		$6.42M Hold
2,406,449
– – 0.23% 56
2021
Q4 		$10.4M Buy
+2,406,449
New +$14.1M 0.49% 46

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rubric Capital Management (New York)'s CTMX Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 2,406,449 shares — an estimated $3.85M sold.

Rubric Capital Management (New York) first reported a position in CTMX in Q4 2021 and held it in 5 quarters. The position peaked at $10.4M in Q4 2021. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Rubric Capital Management (New York) reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 2,406,449 CytomX Therapeutics shares in Q1 2023, an estimated $3.85M.
  • Rubric Capital Management (New York) first reported a position in CytomX Therapeutics in Q4 2021 and held it in 5 quarters.
  • Rubric Capital Management (New York)'s CytomX Therapeutics position peaked at $10.4M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.